James Peyer

Company: Cambrian Biopharma

Job title: Chief Executive Officer

Seminars:

Unlocking the Potential of ATX-304: A Dual AMPK & Mitochondrial Activator for Obesity 10:00 am

Delve into how ATX-304 activates AMPK and mitochondrial pathways to enhance energy expenditure, glucose, and lipid metabolism Review the ongoing Phase 1B study results in pre-diabetic, overweight/obese subjects, focusing on ATX-304’s effects on metabolic health and its potential role in chronic weight managementRead more

day: Conference Day Two